Evaluation of Distinct Freezing Methods and Cryoprotectants for Human Amniotic Fluid Stem Cells Cryopreservation
Carregando...
Citações na Scopus
49
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI PUBLISHING CORPORATION
Autores
DEBES, Adriana de Aguiar
DUARTE, Sergio Aloisio
MORON, Antonio Fernandes
Citação
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, article ID 649353, 10p, 2012
Resumo
Amniotic fluid (AF) was described as a potential source of mesenchymal stem cells (MSCs) for biomedicine purposes. Therefore, evaluation of alternative cryoprotectants and freezing protocols capable to maintain the viability and stemness of these cells after cooling is still needed. AF stem cells (AFSCs) were tested for different freezing methods and cryoprotectants. Cell viability, gene expression, surface markers, and plasticity were evaluated after thawing. AFSCs expressed undifferentiated genes Oct4 and Nanog; presented typical markers (CD29, CD44, CD90, and CD105) and were able to differentiate into mesenchymal lineages. All tested cryoprotectants preserved the features of AFSCs however, variations in cell viability were observed. In this concern, dimethyl sulfoxide (Me2SO) showed the best results. The freezing protocols tested did not promote significant changes in the AFSCs viability. Time programmed and nonprogrammed freezing methods could be used for successful AFSCs cryopreservation for 6 months. Although tested cryoprotectants maintained undifferentiated gene expression, typical markers, and plasticity of AFSCs, only Me2SO and glycerol presented workable viability ratios.
Palavras-chave
Referências
- Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
- ARNAUD FG, 1989, THROMB RES, V53, P585, DOI 10.1016/0049-3848(89)90148-5
- Barzilay R, 2008, STEM CELLS DEV, V17, P547, DOI 10.1089/scd.2007.0172
- DAVIS JM, 1990, BLOOD, V75, P781
- Fauza D, 2004, BEST PRACT RES CL OB, V18, P877, DOI 10.1016/j.bpobgyn.2004.07.001
- FRIEDENS.AJ, 1974, EXP HEMATOL, V2, P83
- In 't Anker PS, 2003, BLOOD, V102, P1548
- Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116
- Liu WX, 2009, REPROD DOMEST ANIM, V44, P788, DOI 10.1111/j.1439-0531.2008.01078.x
- Mareschi K, 2006, EXP HEMATOL, V34, P1563, DOI 10.1016/j.exphem.2006.06.020
- McCullough J, 2010, TRANSFUSION, V50, P808, DOI 10.1111/j.1537-2995.2009.02482.x
- Miranda-Sayago J. M., CRYOBIOLOGY IN PRESS
- Moon JH, 2008, HUM REPROD, V23, P1760, DOI 10.1093/humrep/den202
- Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147
- Ozkavukcu S., 2002, J ANKARA MED SCH, V4, P187
- Prusa A-R., 2002, MED SCI MONITOR, V8, P253
- Prusa AR, 2004, AM J OBSTET GYNECOL, V191, P309, DOI 10.1016/j.ajog.2003.12.014
- Prusa AR, 2003, HUM REPROD, V18, P1489, DOI 10.1093/humrep/deg279
- Rodrigues JP, 2008, CRYOBIOLOGY, V56, P144, DOI 10.1016/j.cryobiol.2008.01.003
- Roubelakis MG, 2007, STEM CELLS DEV, V16, P931, DOI 10.1089/scd.2007.0036
- Seo JM, 2011, CRYOBIOLOGY, V62, P167, DOI 10.1016/j.cryobiol.2011.02.003
- Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44
- Sputtek A, 1997, BEITR INFUS, V34, P79
- Stock P, 2010, NAT PROTOC, V5, P617, DOI 10.1038/nprot.2010.7
- STREUBEL, 1996, WIEN MED WOCHENSCHR, V146, P216
- STRONCEK DF, 1991, TRANSFUSION, V31, P521, DOI 10.1046/j.1537-2995.1991.31691306250.x
- Syme R, 2004, BIOL BLOOD MARROW TR, V10, P135, DOI 10.1016/j.bbmt.2003.09.016
- Tsai MS, 2004, HUM REPROD, V19, P1450, DOI 10.1093/humrep/deh279
- Zangrossi S, 2007, STEM CELLS, V25, P1675, DOI 10.1634/stemcells.2006-0611